Gastrointestinal stromal tumor (GIST)
- Surgery for resectable localized disease
- Imatinib is the key first-line TKI for sensitive KIT/PDGFRA disease
- Mutation testing predicts TKI sensitivity
- Adjuvant imatinib for selected high-risk resected GIST
- Resistance → sequential later-line TKIs
- PDGFRA D842V requires a different targeted strategy
Use at a glance
- Surgery for resectable localized disease
Escalation / refractory disease
- Imatinib is the key first-line TKI for sensitive KIT/PDGFRA disease
- Resistance → sequential later-line TKIs
Practical pearls
- Mutation testing predicts TKI sensitivity
- PDGFRA D842V requires a different targeted strategy
Choosing treatment
- Adjuvant imatinib for selected high-risk resected GIST
Self-check
- What follows GIST TKI resistance?
Sequential later-line TKIs. - Which GIST mutation requires a different targeted strategy?
PDGFRA D842V.
Drugs used for this (2)
All clinical uses · Open Gastrointestinal stromal tumor (GIST) in the interactive console ↗